摘要
目的探讨clusterin表达在淋巴瘤诊断分型中的意义。方法应用组织芯片和免疫组化技术检测clusterin在8例反应性增生淋巴结、175例非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)及18例霍奇金淋巴瘤(Hodgkin’s lymphoma,HL)组织中的表达情况。结果clusterin在193例淋巴瘤中有25例呈阳性表达,其中,18例间变性大细胞淋巴瘤(anaplasia large celllymphoma,ALCL)中有13例呈阳性表达(72·2%),83例弥漫性大B细胞性淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中有12例呈阳性表达(14·5%);clusterin在HL、其他类型NHL和反应性增生淋巴结中均未见表达。结论clusterin可能成为ALCL诊断的新指标,对ALCL的诊断和鉴别诊断具有一定的意义。
Purpose To investigate the value of clusterin expression in diagnosis and subclassification of lymphoma. Methods Immunohistechemistry was used to detect the expression of clusterin on lymphoma tissue micrearrays, which included 18 Hodgkin＇ s lymphoma（HL） ,175 non-Hodgkin＇ s lymphoma（NHL） and 8 benign lymphoid hyperplasia. Results In 193 cases of lymphoma, 25 cases were positive for clusterin. Clusterin immunostaining was observed in 13 of 18 cases of anaplasia large cell lymphoma （ALCL,72. 2% ） and 12 of 83 cases of diffuse large B-cell lymphoma（ DLBCL, 14.5% ）. Clusterin was negative in HL, other subtypes of NHL and benign lymphoid hyperplasia. Conclusions Clusterin may act as a new marker of ALCL. It can play a role in the diagnosis of ALCL and helps to distinguish ALCL from other lymphoid neoplasms.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2006年第3期284-286,共3页
Chinese Journal of Clinical and Experimental Pathology
